Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody
| العنوان: | Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody |
|---|---|
| المؤلفون: | Kazushige Wakuda, Satoshi Ikeda, Masafumi Sata, Ryota Ushio, Kentaro Ito, Takashi Sato, Shigeru Tanzawa, Naoki Furuya, Makoto Nishino |
| المصدر: | Thoracic Cancer Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021) |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, atezolizumab, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, anti‐PD‐L1, 0302 clinical medicine, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, business.industry, Anti pd 1, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Female, Original Article, Nivolumab, business, Cohort study |
| الوصف: | Background Atezolizumab is a programmed death‐ligand 1 (PD‐L1) targeted monoclonal antibody that inhibits PD‐L1 interacting with its receptors PD‐1 and B7‐1, thereby enhancing anticancer immunity. Some real‐world efficacy and safety studies of anti‐PD‐1 antibody have been previously reported. However, there have been no reports investigating the efficacy of atezolizumab monotherapy in clinical practice which have focused on performance status and previous anti‐PD‐1 antibody treatment. Methods We retrospectively reviewed consecutive advanced NSCLC patients who received atezolizumab monotherapy between April 2018 and February 2019 at eight institutions. A total of 152 patients with NSCLC were enrolled in this study. Results A total of 38 patients (25%) had already been treated with anti‐PD‐1 treatment (nivolumab or pembrolizumab) before atezolizumab. The median OS and TTF was 384 days (12.8 months) (95% confidence interval [CI]: 206–424), and 42 days (1.4 months) (95% CI: 27–56) in all patients, respectively. ECOG PS 0 had significantly longer OS (median OS; not reached, p Swimmers plot of atezolizumab according to the efficacy of prior anti‐PD‐1 treatment. Seven patients (18.4%, 7/38) continued atezolizumab over four months as an ICI retreatment. |
| تدمد: | 1759-7714 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3Test https://pubmed.ncbi.nlm.nih.gov/33448648Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....12194075aa42c60389387090977b3ce3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597714 |
|---|